pharmaphorum

AUGUST 12, 2021

A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH) has provided protection for people exposed to malaria parasites for up to nine months. The post More malaria hope as antibody protects against infection appeared first on.

Antibody 64

Antibody Vaccine Vaccination Allergies 64

Scienmag

JANUARY 4, 2021

In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus. Credit: UAB BIRMINGHAM, Ala.

Vaccination 98

Vaccination Vaccine Antibody Development 98

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination 103

Vaccination Vaccine RNA Manufacturing 103

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. Zydus has only said that the vaccine was well tolerated by people who received it in the first phase of the trial.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

Scienmag

AUGUST 24, 2020

An in-depth Garvan study of how the immune system generates effective antibodies provides new insights for vaccine design. Credit: Dr Ofir Shein-Lumbroso, Garvan Institute of Medical Research An in-depth Garvan study of how the immune system generates effective antibodies provides new insights for vaccine design.

Antibody 67

Antibody Vaccination Vaccine Research 67

Scienmag

JUNE 3, 2021

Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2)

Antibody 41

Antibody Vaccination Vaccine Allergies 41

pharmaphorum

OCTOBER 18, 2021

An FDA advisory committee voted unanimously in favour of a booster dose of Johnson & Johnson’s one-shot COVID-19 vaccine on Friday, as panellists suggested it should have been used as a two-dose regimen from the start. All told, 15 million people in the US have been vaccinated with Ad26.COV2.S,

Vaccination 92

Vaccination Vaccine Allergies Antibody 92

Pharmaceutical Technology

DECEMBER 16, 2022

Novel therapeutics and vaccines for malaria. In September, researchers from Oxford University shared their findings from a Phase IIb study with a more efficacious malaria vaccine called R21, which met the WHO’s 75% efficacy threshold. Both vaccines are based on recombinant proteins and attack the parasite during the sporozoite stage.

Development 264

Development Drugs Vaccination Vaccine 264

Scienmag

MAY 12, 2021

Scripps Research scientists propose an innovative vaccine approach to protect against a troublesome family of viruses that present a major global health risk LA JOLLA, CA–Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses (..)

Vaccination 47

Vaccination Vaccine Antibody Scientist 47

Scienmag

MARCH 25, 2021

The largest study of its kind to date also found benefit for lactating women BOSTON – In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA COVID-19 vaccines to be highly effective in […].

Immune Response 69

Immune Response Vaccination Vaccine Antibody 69

Scienmag

JULY 1, 2021

Over years of studying antibody responses against the flu in the Wilson lab at the University of Chicago, researchers kept coming up with a strange finding: antibodies that seemed to bind not only to the flu virus, but to every virus the lab could throw at them. Since antibodies are usually highly specific to individual […].

Antibody 40

Antibody Vaccination Vaccine Research 40

Scienmag

MAY 27, 2021

A special type of antibody is produced in patients who’ve had COVID-19 as well as less-serious coronaviruses that cause colds. LA JOLLA, CA–Even before the COVID-19 pandemic, most people in the United States already had been sick with a coronavirus, albeit a far less dangerous one.

Antibody 50

Antibody Vaccination Vaccine Allergies 50

Scienmag

JULY 23, 2021

Vaccines against COVID-19, which […].

Antibody 75

Antibody Protein Vaccination Vaccine 75

Scienmag

FEBRUARY 25, 2021

Research from the California Institute of Technology shows exactly how antibodies stick to and block the Zika virus, which will inform vaccine development Credit: Image courtesy of Shannon Esswein.

Antibody 52

Antibody Scientist Vaccination Vaccine 52

Scienmag

OCTOBER 2, 2020

Credit: Virginia Tech Renowned tick immunobiologist Utpal Pal wants to ad apt the rabies vaccination platform to produce antibodies that can protect against Borrelia burgdorferi, the bacteria responsible for Lyme disease. The intention is to apply this work to other tick-borne diseases in the future.

Vaccination 88

Vaccination Vaccine Bacteria Development 88

pharmaphorum

AUGUST 3, 2020

While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations. The post Lilly’s antibody for COVID-19 protection starts nursing home trial appeared first on.

Nurses 59

Nurses Antibody Trials Clinical Trials 59

Scienmag

DECEMBER 16, 2020

Scientists at the Ragon Institute of MGH, MIT and Harvard find that neutralizing antibody potency predicts severe or fatal COVID-19. BOSTON — Understanding the body’s immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines.

Antibody 40

Antibody Immune Response Scientist Vaccination 40

Scienmag

AUGUST 17, 2020

. — University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies. These antibodies may contribute to some of the negative side effects of long-term opioid use.

Antibody 50

Antibody Scientist Vaccination Vaccine 50

Scienmag

FEBRUARY 18, 2021

Researchers at the Ragon Institute of MGH, MIT and Harvard and Massachusetts General Hospital show that levels of specific antibodies developed in the immune response may influence COVID-19 outcomes in both children and adults.

Antibody 74

Antibody Immune Response Development Research 74

Pharmaceutical Technology

JUNE 9, 2023

Also known as palivizumab, Sobi ‘s Synagis was the first FDA-approved monoclonal antibody used in children at high risk of RSV disease. After a long period without any new approvals, in May, the FDA approved GSK’s vaccine Arexvy for the prevention of LRTD caused by RSV in individuals 60 and older.

FDA Approval 147

FDA Approval Antibody Allergies Packaging 147

Scienmag

JANUARY 10, 2021

January 11, 2021) – To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus. Credit: Kim Ratliff, Augusta University AUGUSTA, Ga.

Vaccination 59

Vaccination Vaccine Antibody Scientist 59

Scienmag

JANUARY 25, 2021

OHSU study has important implications for vaccines, diagnosis of COVID-19 A new study demonstrates that antibodies generated by the novel coronavirus react to other strains of coronavirus and vice versa, according to research published today by scientists from Oregon Health & Science University.

Antibody 40

Antibody Scientist Vaccination Vaccine 40

Scienmag

MARCH 5, 2021

Scientists at Walter Reed Army Institute of Research, in a collaboration the Duke University, have confirmed that monoclonal antibodies can be an effective tool in the global fight against malaria.

Scientist 74

Scientist Antibody Research Allergies 74

Scienmag

NOVEMBER 6, 2020

New study demonstrates candidate’s potential to generate antibodies, limit viral shedding Credit: Craig Chandler, University of Nebraska-Lincoln A genetically edited form of a herpes simplex virus — rewired to keep it from taking refuge in the nervous system and eluding an immune response — has outperformed a leading vaccine candidate (..)

Vaccination 49

Vaccination Vaccine Immune Response Genetics 49

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Bioengineer

JULY 23, 2021

Intranasal vaccination is needle-free and elicits immunity at the site of infection, the respiratory tract. – There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., Credit: UAB.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Pharmaceutical Technology

AUGUST 5, 2022

This list includes the monoclonal antibody (mAb) PRN100 developed at University College London (UCL) and ALX-002, a treatment developed by Allyx Therapeutics that is also being studied for Alzheimer’s disease. According to Mabbott, a challenge with developing mAbs or vaccines is their potential toxicity.

Drugs 299

Drugs Protein Vaccination Vaccine 299

Scienmag

MAY 27, 2021

New Penn Medicine study shows how T cells compensate when other immune cells go down PHILADELPHIA–Antibodies aren’t the only immune cells needed to fight off COVID-19 — T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with […]. (..)

Antibody 54

Antibody Medicine Clinical Trials Clinical Trials 54

Scienmag

JANUARY 7, 2021

ANN ARBOR–A team of researchers has discovered an antibody that blocks the ability of the dengue virus to cause disease in mice. The findings open the potential for developing effective treatments and designing a vaccine for dengue and similar diseases.

Antibody 40

Antibody Research Vaccination Vaccine 40

Scienmag

JULY 6, 2021

Studies reveal unprecedented mechanism behind loss of antibody neutralization against this pandemic coronavirus variant of concern Credit: Young-Jun Park, UW Department of Biochemistry Three mutations in the Epsilon coronavirus spike protein dampen the neutralizing potency of antibodies induced by current vaccines or past COVID infections.

Antibody 98

Antibody Protein Vaccination Vaccine 98

The Pharma Data

JULY 6, 2021

Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. Demonstrated strong neutralizing antibody activity against the Delta (B.1.617.2)

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

Scienmag

SEPTEMBER 4, 2020

The new paper reports the findings of two open-label, non-randomised phase 1/2 trials looking at a frozen formulation and a freeze-dried formulation of a two-part vaccine.

Vaccination 45

Vaccination Vaccine Trials Antibody 45

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Wed, 11/02/2022 - 15:44. Thursday, November 03, 2022 - 06:45am. Ugur Sahin, M.D.,

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

Scienmag

FEBRUARY 10, 2021

Antibodies that react to both ordinary coronaviruses and SARS-CoV-2 are common in the population but don’t neutralize the COVID-19-causing virus PHILADELPHIA — Past exposure to seasonal coronaviruses (CoVs), which cause the common cold, does not result in the production of antibodies that protect against the novel coronavirus SARS-CoV-2, (..)

Antibody 45

Antibody Production Allergies Vaccine 45

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. It is now following up with data from a small group of older adults, and they look positive.

Vaccination 53

Vaccination Vaccine Research Trials 53

Pfizer

DECEMBER 8, 2022

FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza. INDICATION & AUTHORIZED USE Pfizer-BioNTech COVID-19 Vaccine, Bivalent, (Original and Omicron BA.4/BA.5) AUTHORIZED USE .

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

The Pharma Data

JULY 8, 2021

Johnson & Johnson (NYSE: JNJ) (the Company) announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. ” Demonstrated strong neutralizing antibody activity against the Delta (B.1.617.2)

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52